Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib Extension Study in Moderate to Severe Hidradenitis Suppurativa
NCT07665437Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Jul 2026
- Primary completion
- Oct 2031
- Countries
- 9
01
Overview
A Phase 3 trial of remibrutinib in hidradenitis suppurativa (HS), sponsored by Novartis. Started Jul 2026; status: recruiting.
02
Drugs
remibrutinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT07665437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07665437.